Open EyeBeta

A public record of U.S. government and large ownership

Brand

INVEGA SUSTENNA

INVEGA SUSTENNA, also sold as XEPLION, and the longer-acting INVEGA TRINZA and TREVICTA, are treatments for schizophrenia. Johnson & Johnson's fiscal 2025 Form 10-K lists them as key Innovative Medicine products.

PharmaceuticalsHealthcare

Also searched as XEPLION, INVEGA TRINZA, TREVICTA.

Documented stakes

  • Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies.

    As of Dec 28, 2025. Last checked Sep 22, 2026.